Evidence map›Paper›PMID 22643351›Full record

ArticleGastroenterology2012

A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.

Gerold Bongers, Luciana R Muniz, Michelle E Pacer, Alina C Iuga, Nanthakumar Thirunarayanan, Erik Slinger, Martine J Smit, E Premkumar Reddy, Lloyd Mayer, Glaucia C Furtado and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Establishment of Intestinal Organoid fromInternational journal of molecular sciences · 2021
    Article
  5. Article
  6. Correlations of morphology and molecular alterations in traditional serrated adenoma.World journal of gastrointestinal pathophysiology · 2020
    Review
  7. Article
  8. Roles for HB-EGF in Mesenchymal Stromal Cell Proliferation and Differentiation During Skeletal Growth.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Gerold BongersImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Luciana R MunizImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Michelle E PacerImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Alina C IugaDivision of Gastrointestinal Pathology, Department of Pathology, The Mount Sinai Medical Center, New York, New York.
Nanthakumar ThirunarayananImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Erik SlingerImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Martine J SmitLeiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, Amsterdam, The Netherlands.
E Premkumar ReddyDepartment of Oncological Sciences, Mount Sinai School of Medicine, New York, New York.
Lloyd MayerImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Glaucia C FurtadoImmunology Institute, Mount Sinai School of Medicine, New York, New York.
Noam HarpazDivision of Gastrointestinal Pathology, Department of Pathology, The Mount Sinai Medical Center, New York, New York.
Sergio A LiraImmunology Institute, Mount Sinai School of Medicine, New York, New York. Electronic address: sergio.lira@mssm.edu.
Mount Sinai Hospital · USIcahn School of Medicine at Mount Sinai · USMount Sinai Medical Center · US

Funding

THE ROLE OF ICSBP IN MUCOSAL IMMUNE RESPONSEP01DK072201 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HARPAZ, NOAM · 2006 to 2015
$14.6M
Molecular pathogenesis of intestinal serrated polypsR01CA161373 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LIRA, SERGIO A. · 2011 to 2020
$3.7M
NCI NIH HHS 1R01CA161373-01NCI NIH HHS R01 CA161373NIDDK NIH HHS P01 DK072201
6 · The paper itself

Abstract

BACKGROUND &

aimsEpithelial cancers can be initiated by activating mutations in components of the mitogen-activated protein kinase signaling pathway such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or epidermal growth factor receptor (EGFR). Human intestinal serrated polyps are a heterogeneous group of benign lesions, but some progress to colorectal cancer. Tumors that arise from these polyps frequently contain activating mutations in BRAF or KRAS, but little is known about the role of EGFR activation in their development.

methodsPolyp samples were obtained from adults during screening colonoscopies at Mount Sinai Hospital in New York. We measured levels of EGFR protein and phosphorylation in human serrated polyps by immunohistochemical and immunoblot analyses. We generated transgenic mice that express the ligand for EGFR, Heparin-binding EGF-like growth factor (HB-EGF), in the intestine.

resultsEGFR and the extracellular-regulated kinases (ERK)1/2 were phosphorylated in serrated areas of human hyperplastic polyps (HPPs), sessile serrated adenomas, and traditional serrated adenomas. EGFR and ERK1/2 were phosphorylated in the absence of KRAS or BRAF activating mutations in a subset of HPP. Transgenic expression of the EGFR ligand HB-EGF in the intestines of mice promoted development of small cecal serrated polyps. Mice that expressed a combination of HB-EGF and US28 (a constitutively active, G-protein-coupled receptor that increases processing of HB-EGF from the membrane) rapidly developed large cecal serrated polyps. These polyps were similar to HPPs and had increased phosphorylation of EGFR and ERK1/2 within the serrated epithelium. Administration of pharmacologic inhibitors of EGFR or MAPK to these transgenic mice significantly reduced polyp development.

conclusionsActivation of EGFR signaling in the intestine of mice promotes development of serrated polyps. EGFR signaling also is activated in human HPPs, sessile serrated adenomas, and traditional serrated adenomas.

Indexed as

Signal TransductionAdenomaAnimalsBlotting, WesternCaco-2 CellsColonoscopyEnzyme ActivationErbB ReceptorsHeparin-binding EGF-like Growth FactorHumansHyperplasiaImmunohistochemistryIntercellular Signaling Peptides and ProteinsIntestinal MucosaIntestinal NeoplasmsIntestinal PolypsBRAF protein, humanEGFR protein, humanEGFR protein, mouseErbB ReceptorsHBEGF protein, humanHbegf protein, mouseHbegf protein, ratHeparin-binding EGF-like Growth FactorIntercellular Signaling Peptides and ProteinsKRAS protein, humanLigandsMAPK1 protein, humanMapk1 protein, mouseMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Protein Kinase InhibitorsProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsReceptors, G-Protein-CoupledRecombinant Fusion Proteins

Identifiers

PMID22643351
PMCPMC3431560
OpenAlexW2083535640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.